Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 11:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetes Mellitus, Gastroparesis With Diabetes Mellitus, Gastroparesis
Interventions
Pyloromyotomy
Procedure
Lead sponsor
Matthew Allemang
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Gastroparesis
Interventions
GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet), Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Concord, California • Indianapolis, Indiana • Chevy Chase, Maryland + 6 more
Conditions
Diabetic Gastroparesis, Idiopathic Gastroparesis, Gastroparesis Postoperative
Interventions
Gastric Per Oral Endoscopic Myotomy
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Phase 3 Interventional Results available

Diabetic Gastroparesis Study 05

NCT03786380
Conditions
Gastroparesis
Interventions
Relamorelin 10 μg
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
189
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 157 more
Conditions
Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
30
States / cities
Dothan, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 27 more
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
Placebo, Relamorelin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
183
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 144 more
Completed Not applicable Interventional Results available

Transcutaneous Electrical Acustimulation (TEA) for Gastroparesis

NCT05362578
Conditions
Gastroparesis With Diabetes Mellitus
Interventions
transcutaneous electrical accustimulation at treatment point., transcutaneous electrical accustimulation at sham point.
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
5% dextrose in water, TZP-101
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
San Francisco, California • Anderson, Indiana • Kansas City, Kansas + 3 more
Conditions
Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
Interventions
Enterra Therapy System
Device
Lead sponsor
Enterra Medical, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Tampa, Florida • Louisville, Kentucky • Detroit, Michigan + 3 more
Conditions
Gastroparesis
Interventions
Placebo, Camicinal
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Chandler, Arizona • Long Beach, California • Northridge, California + 29 more
Conditions
Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions
Relamorelin, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
70
States / cities
Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 58 more
Terminated No phase listed Observational Accepts healthy volunteers

GI-Challenge Study for Gastroparesis Patients and Healthy Controls

NCT03896126
Conditions
Gastroparesis
Interventions
Observational
Other
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 49 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Diabetic Gastroparesis
Interventions
CGMS and insulin pump
Device
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
San Francisco, California • Stanford, California • Ann Arbor, Michigan + 4 more
Completed Not applicable Interventional Results available

Thoracic Neuromodulation for Diabetic Gastroparesis

NCT05273788
Conditions
Diabetic Gastroparesis
Interventions
2400 ThorS-MagNT Stimulations at 1Hz, 2400 ThorS-MagNT Stimulations at 10Hz, Sham Stimulations
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Gastroparesis, Diabetic Gastroparesis
Interventions
Tradipitant
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
U.S. locations
15
States / cities
Maitland, Florida • Tampa, Florida • Wauconda, Illinois + 12 more
Conditions
Gastroparesis
Interventions
Naronapride, Placebo
Drug
Lead sponsor
Dr. Falk Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Chula Vista, California • Lomita, California • Clearwater, Florida + 16 more
Conditions
Gastroparesis, Diabetic Gastroparesis, Nausea, Vomiting
Interventions
tadalafil
Drug
Lead sponsor
Mark Feinglos
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of Promethazine for Treatment of Diabetic Gastroparesis

NCT02130622
Conditions
Diabetic Gastroparesis
Interventions
Promethazine, Sugar pill
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-906 Maleate, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
67
States / cities
Dothan, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Conditions
Diabetic Gastroparesis
Interventions
Nimacimab, Placebo
Drug
Lead sponsor
Bird Rock Bio, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Miami, Florida • Wichita, Kansas • Rochester, Minnesota + 1 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis

NCT04762719
Conditions
Diabetes, Gastroparesis With Diabetes Mellitus
Interventions
PET/CT Scan with 11C-ER176, Core biopsy of gastric muscle
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Gastroparesis
Interventions
CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3, Placebo
Drug
Lead sponsor
CinDome Pharma, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Chula Vista, California • Jacksonville, Florida • Miami, Florida + 15 more
Conditions
Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Placebo, 10mg TZP-102, 20mg TZP-102
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 27 more
Conditions
Diabetic Gastroparesis
Interventions
Metoclopramide Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 45 more